Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Payables (2016 - 2025)

Editas Medicine (EDIT) has disclosed Payables for 11 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 74.68% to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 74.68% decrease, with the full-year FY2024 number at $5.5 million, down 33.57% from a year prior.
  • Payables was $3.2 million for Q3 2025 at Editas Medicine, down from $6.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $13.8 million in Q2 2024 to a low of $3.2 million in Q3 2025.
  • A 5-year average of $7.4 million and a median of $6.8 million in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: surged 100.94% in 2022, then crashed 74.68% in 2025.
  • Editas Medicine's Payables stood at $5.0 million in 2021, then soared by 88.34% to $9.5 million in 2022, then fell by 13.06% to $8.3 million in 2023, then plummeted by 33.57% to $5.5 million in 2024, then crashed by 42.42% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Payables are $3.2 million (Q3 2025), $6.7 million (Q2 2025), and $5.5 million (Q1 2025).